Reuters logo
Sanofi, UCB set up drug development partnership
March 11, 2014 / 6:15 AM / 4 years ago

Sanofi, UCB set up drug development partnership

PARIS (Reuters) - French and Belgian drugmakers Sanofi and UCB have entered a partnership aimed at finding treatments for so-called immune-mediated diseases in areas such as rheumatoid arthritis and inflammatory bowel conditions.

The two companies would share costs and profits on a 50:50 basis, Sanofi said in a statement on Tuesday.

UCB will be entitled to initial upfront, preclinical and clinical development milestone payments from Sanofi that could exceed 100 million euros ($139 million), Sanofi added.

($1 = 0.7205 Euros)

Reporting by James Regan; Editing by Blaise Robinson

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below